We have located links that may give you full text access.
Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth.
British Journal of Pharmacology 2019 Februrary 15
BACKGROUND AND PURPOSE: Induced cyclooxygenase-2 (COX-2) in malignant gliomas causes excessive synthesis of prostaglandin E2 (PGE2 ) that is thought to facilitate the brain tumor growth and invasion. However, which downstream PGE2 receptor subtype (i.e., EP1-EP4) directly contributes to COX activity-promoted glioma growth remains largely unknown.
EXPERIMENTAL APPROACH: Using a publicly available database from The Cancer Genome Atlas (TCGA) research network, we compared the expression of PGE2 signaling-associated genes in human lower-grade glioma (LGG) and glioblastoma multiforme (GBM) samples. The Kaplan-Meier analysis was performed to determine the relationship between their expression and survival probability. A time-resolved fluorescence resonance energy transfer (TR-FRET) method was used to identify the PGE2 receptor subtype that mediates COX-2/PGE2 -initiated cAMP signaling in human GBM cells. Taking advantage of a novel selective bioavailable brain-permeable small-molecule antagonist that we recently reported, the effect of pharmacological inhibition of EP2 receptor on glioma cell growth in vitro and in vivo was studied.
KEY RESULTS: EP2 is a key Gαs -coupled receptor that mediates COX-2/PGE2 -initiated cAMP signal pathways in human malignant glioma cells. Inhibition of EP2 receptor reduces COX-2 activity-driven GBM cell proliferation, invasion and migration, and causes cell-cycle arrest at G0-G1 and apoptosis of the GBM cells. Glioma cell growth in vivo is also substantially decreased by post-treatment of the EP2 antagonist in both subcutaneous and intracranial tumor models.
CONCLUSION AND IMPLICATIONS: Our results together suggest that PGE2 signaling via EP2 receptor increases the malignant potential of human glioma cells and might represent a novel therapeutic target for GBM.
EXPERIMENTAL APPROACH: Using a publicly available database from The Cancer Genome Atlas (TCGA) research network, we compared the expression of PGE2 signaling-associated genes in human lower-grade glioma (LGG) and glioblastoma multiforme (GBM) samples. The Kaplan-Meier analysis was performed to determine the relationship between their expression and survival probability. A time-resolved fluorescence resonance energy transfer (TR-FRET) method was used to identify the PGE2 receptor subtype that mediates COX-2/PGE2 -initiated cAMP signaling in human GBM cells. Taking advantage of a novel selective bioavailable brain-permeable small-molecule antagonist that we recently reported, the effect of pharmacological inhibition of EP2 receptor on glioma cell growth in vitro and in vivo was studied.
KEY RESULTS: EP2 is a key Gαs -coupled receptor that mediates COX-2/PGE2 -initiated cAMP signal pathways in human malignant glioma cells. Inhibition of EP2 receptor reduces COX-2 activity-driven GBM cell proliferation, invasion and migration, and causes cell-cycle arrest at G0-G1 and apoptosis of the GBM cells. Glioma cell growth in vivo is also substantially decreased by post-treatment of the EP2 antagonist in both subcutaneous and intracranial tumor models.
CONCLUSION AND IMPLICATIONS: Our results together suggest that PGE2 signaling via EP2 receptor increases the malignant potential of human glioma cells and might represent a novel therapeutic target for GBM.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app